Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Trial Identifier: D8400C00001
Sponsor: Alexion Pharmaceuticals, Inc.
Start Date: July 2026
Primary Completion Date: March 2030
Study Completion Date: March 2030

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.